Press Releases CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Delayed Hong Kong S.E. Other stock markets 01:00:17 2024-05-02 am EDT			5-day change	1st Jan Change
6.15 ^HKD	+3.54%		+31.13%	-5.38%

Apr. 29	CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations	CI
Apr. 12	Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CARsgen Submitted Responses to FDA Observations	Apr. 30	AQ
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma	Mar. 04	AQ
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection	Jan. 16	AQ
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed, Refractory Multiple Myeloma or Relapsed, Refractory Primary Plasma Cell Leukemia	Dec. 05	AQ
CARsgen Announces Formation of its Clinical Advisory Board	Nov. 21	AQ
CARsgen Announced 2023 Interim Results	23-08-23	AQ
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer	23-05-05	PR
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer	23-04-20	PR
CARsgen Announced 2022 Annual Results and Business Updates	23-03-23	AQ
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer	23-01-31	PR
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI	23-01-23	AQ
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China	23-01-16	PR
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs	22-10-31	PR
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology	22-08-18	PR
CARsgen Appoints Dr. Hua Jiang as Executive Director	22-08-02	PR
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers	22-05-10	PR
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer	22-04-07	PR
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China	22-03-23	PR
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China	22-03-03	PR
CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production	22-02-21	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Press Releases

Filters